US 12,078,641 B2
Biomarkers useful in the treatment of subjects having diseases of the eye
Peter A. Campochiaro, Baltimore, MD (US); and Lili Lu, Joppa, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Jan. 24, 2022, as Appl. No. 17/582,286.
Application 17/582,286 is a division of application No. 15/523,657, granted, now 11,268,964, previously published as PCT/US2015/060172, filed on Nov. 11, 2015.
Claims priority of provisional application 62/078,138, filed on Nov. 11, 2014.
Claims priority of provisional application 62/188,377, filed on Jul. 2, 2015.
Prior Publication US 2022/0146533 A1, May 12, 2022
Int. Cl. G01N 33/68 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01)
CPC G01N 33/6893 (2013.01) [C12Y 115/01001 (2013.01); G01N 33/50 (2013.01); G01N 33/573 (2013.01); G01N 33/6827 (2013.01); G01N 2333/90283 (2013.01); G01N 2800/164 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01); G01N 2800/7009 (2013.01)] 6 Claims
OG exemplary drawing
 
1. A method for treating a subject having retinitis pigmentosa comprising:
a) obtaining a biological sample from the subject;
b) providing a control biological sample;
c) measuring one or more of the following: cupric reducing antioxidant capacity, GSH/GSSG ratio, carbonyl adduct level in the sample of a) and b);
d) comparing the one or more measurements of c) in the sample from the subject to the control sample;
e) quantifying or staging the severity of the disease in the subject as progressing in stage, or increasing in severity, if the levels of cupric reducing antioxidant capacity and/or GSH/GSSG ratio is reduced relative to the control sample, and/or if the levels of carbonyl adduct level is elevated relative to the control sample; and
f) selecting a course of treatment for the disease in the subject which is based on the stage or severity of disease indicated in e), wherein the treatment includes administering an effective treatment to the subject having retinitis pigmentosa, wherein the effective treatment comprises N-Acetylcysteine Amide (NACA).